News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx to Present at the 36th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer,
View HTML
Toggle Summary ChemoCentryx to Participate at the Piper Jaffray 29th Annual Healthcare Conference
MOUNTAIN VIEW, Calif. , Nov. 17, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer,
View HTML
Toggle Summary ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights
-- Phase III ADVOCATE trial of avacopan remains on track to complete enrollment in mid-2018 -- -- Patient enrollment ongoing in registration-supporting trial for avacopan in the treatment C3 Glomerulopathy (C3G) -- -- Plan to launch registration-supporting trial for CCX140 in the treatment of Focal
View HTML
Toggle Summary Presentations at ASN Kidney Week 2017 Highlight ChemoCentryx Platform in Treatment of Kidney Diseases ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)
-- Rapid reduction in kidney inflammation following avacopan treatment in patients with ANCA-Associated Vasculitis revealed by analysis of markers of kidney damage -- -- Podocyte protection demonstrated with CCR2 inhibitor CCX140, supporting differentiated potential treatment option for patients
View HTML
Toggle Summary ChemoCentryx to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 7, 2017
MOUNTAIN VIEW, Calif. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that the Company's third quarter 2017 financial results will be released
View HTML
Toggle Summary ChemoCentryx to Present at Three Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer,
View HTML
Toggle Summary ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights
-- Pivotal Phase III ADVOCATE trial of avacopan on track to complete enrollment in mid-2018 as projected -- -- Launching second trial of avacopan in patients with C3 Glomerulopathy (C3G) -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif. , Aug.
View HTML
Toggle Summary ChemoCentryx to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 8, 2017
MOUNTAIN VIEW, Calif. , July 26, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that the Company's second quarter 2017 financial results will be released
View HTML
Toggle Summary Oral Presentations at ERA-EDTA Congress Highlight Fourth Potential Indication for Avacopan and Potential for CCR2 Inhibition in Focal Segmental Glomerulosclerosis (FSGS)
-- Clinical Study Shows Drop in Proteinuria in Patients Treated with Avacopan for IgA Nephropathy (IgAN) -- -- Potential of CCR2 Inhibitor as a Therapeutic Treatment Option for FSGS Validated -- MOUNTAIN VIEW, Calif. , June 06, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.
View HTML
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , May 24, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will
View HTML